WO1998057946A1 - Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors) - Google Patents
Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors) Download PDFInfo
- Publication number
- WO1998057946A1 WO1998057946A1 PCT/US1998/011503 US9811503W WO9857946A1 WO 1998057946 A1 WO1998057946 A1 WO 1998057946A1 US 9811503 W US9811503 W US 9811503W WO 9857946 A1 WO9857946 A1 WO 9857946A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- bromo
- mmol
- tumor cells
- cells
- Prior art date
Links
- 0 CC*(C)(C)CC*(C)(C)C(c1c(C)cc(C)c(*)c1CC1)c2c1cc(*)c*2O Chemical compound CC*(C)(C)CC*(C)(C)C(c1c(C)cc(C)c(*)c1CC1)c2c1cc(*)c*2O 0.000 description 9
- MSYUUMDYPLTMRV-UHFFFAOYSA-N Cc(cc1CCc2cc(Br)cnc22)ccc1C2=C1CCNCC1 Chemical compound Cc(cc1CCc2cc(Br)cnc22)ccc1C2=C1CCNCC1 MSYUUMDYPLTMRV-UHFFFAOYSA-N 0.000 description 2
- YMAPJTWNCZOASX-UHFFFAOYSA-N Cc1ccc(C(C2CCNCC2)c(c(CC2)c3)ncc3Br)c2c1 Chemical compound Cc1ccc(C(C2CCNCC2)c(c(CC2)c3)ncc3Br)c2c1 YMAPJTWNCZOASX-UHFFFAOYSA-N 0.000 description 2
- HNTURGSTLUYJMN-UHFFFAOYSA-N Brc1cnc(C(c2ccc(C3CC3)c(Br)c2CC2)N3CCNCC3)c2c1 Chemical compound Brc1cnc(C(c2ccc(C3CC3)c(Br)c2CC2)N3CCNCC3)c2c1 HNTURGSTLUYJMN-UHFFFAOYSA-N 0.000 description 1
- QMXLGZWKGUAQOC-UHFFFAOYSA-N CC(C1[Br]=C)C(C)=CC(CCc2c3)=C1C(C1CCNCC1)c2ncc3Br Chemical compound CC(C1[Br]=C)C(C)=CC(CCc2c3)=C1C(C1CCNCC1)c2ncc3Br QMXLGZWKGUAQOC-UHFFFAOYSA-N 0.000 description 1
- YGRQFBRFHZRHKH-JGCGQSQUSA-N O=C(Cc(ccnc1)c1C(OCc1ccccc1)=O)N(CC1)CCC1[C@H](c(c(CCc1c2)cc(Cl)c3)c3Br)c1ncc2Br Chemical compound O=C(Cc(ccnc1)c1C(OCc1ccccc1)=O)N(CC1)CCC1[C@H](c(c(CCc1c2)cc(Cl)c3)c3Br)c1ncc2Br YGRQFBRFHZRHKH-JGCGQSQUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- R can be pyridylmethyl or an N-oxide thereof; optional substitution on the pyridyl ring is disclosed.
- the compounds are said to be useful for inhibiting farnesyl protein transferase.
- Q and T are independently selected from halo
- W and V are independently selected from H and halo, provided that at least one of W and V is H;
- R 1 is H or alkyl
- X represents N, CH, or C when the double bond is present at the C-11 position
- R is -OR3, -NR3R4 or -SR 3 ;
- R 3 and R 4 are independently selected form the group consisting of H, alkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl.
- N-Oxides of formulas IA, IB and IC are represented by the following structures:
- Compounds of formula I can also form an N-oxide at the pyridinyl ring designated ring I in the tricyclic portion of the structure, and can also form di-oxides, wherein the pyridinyl ring in the tricyclic portion and the pendant pyridyl ring are both N-oxides.
- ring I pyridinyl ring
- IC IC and the corresponding N-oxides
- Q is Br, T is halo and W is halo; or Q is Br, T is halo and V is halo; or Q is Br, T is halo and W and V are each H.
- T is preferably Br or Cl.
- W or V is halo, it is preferably Br or Cl.
- X is preferably N or CH.
- R 1 is preferably H.
- the compounds of this invention (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro; (ii) block the phenotypic change induced by a form of transforming Ras which is a farnesyl acceptor but not by a form of transforming Ras engineered to be a geranylgeranyl acceptor; (iii) block intracellular processing of Ras which is a farnesyl acceptor but not of Ras engineered to be a geranylgeranyl acceptor; and (iv) block abnormal cell growth in culture induced by transforming Ras.
- the compounds of this invention inhibit farnesyl protein transferase and the farnesylation of the oncogene protein Ras.
- This invention further provides a method of inhibiting ras farnesyl protein transferase, in mammals, especially humans, by the administration of an effective amount of the tricyclic compounds described above.
- the administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase, is useful in the treatment of the cancers described below.
- This invention provides a method for inhibiting or treating the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of this invention.
- Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition).
- This invention also provides a method for inhibiting or treating tumor growth by administering an effective amount of the tricyclic compounds, described herein, to a mammal (e.g., a human) in need of such treatment.
- this invention provides a method for inhibiting or treating the growth of tumors expressing an activated Ras oncogene by the administration of an effective amount of the above described compounds.
- tumors which may be inhibited or treated include, but are not limited to, breast cancer, prostate cancer, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma and epidermal carcinoma.
- lung cancer e.g., lung adenocarcinoma
- pancreatic cancers e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma
- colon cancers e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma
- this invention also provides a method for inhibiting or treating proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes--i.e., the Ras gene itself is not activated by mutation to an oncogenic form--with said inhibition or treatment being accomplished by the administration of an effective amount of the tricyclic compounds described herein, to a mammal (e.g., a human) in need of such treatment.
- a mammal e.g., a human
- the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited or treated by the tricyclic compounds described herein.
- the tricyclic compounds useful in the methods of this invention inhibit or treat the abnormal growth of cells.
- these compounds may function through the inhibition of G-protein function, such as ras p21 , by blocking G-protein isoprenylation, thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer.
- G-protein function such as ras p21
- G-protein isoprenylation thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer.
- these compounds inhibit ras farnesyl protein transferase, and thus show antiproliferative activity against ras transformed cells.
- MH+ represents the molecular ion plus hydrogen of the molecule in the mass spectrum
- solvents and reagents may be referred to herein by the abbreviations indicated: tetrahydrofuran (THF); ethanol (EtOH); methanol (MeOH); acetic acid (HOAc or AcOH); ethyl acetate (EtOAc); N,N-dimethylformamide (DMF); trifluoroacetic acid (TFA); trifluoroacetic anhydride (TFAA); 1 -hydroxybenzotriazole (HOBT); m-chloroperbenzoic acid (MCPBA); triethylamine (Et 3 N); diethyl ether (Et 2 0); ethyl chloroformate (CICO2E1); and 1 -(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (DEC).
- THF tetrahydrofuran
- EtOH ethanol
- MeOH methanol
- EtOAc acetic acid
- Representative compounds of the invention include:
- Certain tricyclic compounds will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.
- Certain basic tricyclic compounds also form pharmaceutically acceptable salts, e.g., acid addition salts.
- the pyrido- nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids.
- suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art.
- the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
- the free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
- a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
- the free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention. All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purpopses of the invention.
- Compounds of the invention may be made by the methods described in the examples below, and by the methods described in WO 95/10516 -- see, for example, the methods for preparing compounds of Formula 400.00 ⁇ and in WO 96/30363.
- Compounds of formula la can be converted to other compounds of formula I by methods well known in the art.
- the benzyl group can be removed by treatment with trimethylsilyl iodide to obtain the corresponding carboxy-substituted compound (i.e., compounds of formula IA wherein R 3 is H).
- a carboxy-substituted compound can be reacted with an amine under standard coupling conditions to obtain an amide (i.e., compounds of formula IB), or can be esterified under standard conditions to obtain corresponding compounds of formula IA wherein R 3 is alkyl.
- a carboxy-substituted compound can be reacted with a suitable base (e.g., K2CO3) and either an aralkyl halide or a heteroaralkyl halide in a solvent such as DMF to obtain the corresponding aralkyl or heteroaraklyl esters.
- Aryl esters can be prepared by condensing the appropriate phenol or phenoxide with the carboxy compound and a suitable coupling agent.
- Thioesters can be prepared, for example, by reacting the carboxy- substituted compound with diethylcyanophosphonate, E-3N and the appropriate thiol as described in J. Or ⁇ . Chem.. 39, 22 (1974), p. 3302- 3303.
- N-oxide compounds of formulas IA to IC can be prepared by coupling compounds of formula II with lithium 3-(benzyloxycarbonyl)- pyridyl N-oxide acetate (prepared by MCPBA oxidation of lithium 3- (benzyloxycarbonyl)-pyridylacetate using a procedure similar to that decribed below).
- the organic solvent solution of formula II is cooled to about 0°C before the MCPBA is added.
- the reaction is then allowed to warm to room temperature during the reaction period.
- the desired product can be recovered by standard separation means, for example, the reaction mixture can be washed with an aqueous solution of a suitable base, e.g., saturated NaHC ⁇ 3 or NaOH (e.g., i N NaOH), and then dried over anhydrous MgS ⁇ 4.
- the solution containing the product can be concentrated in vacuo, and the product can be purified by standard means, e.g., by chromatography using silica gel (e.g., flash column chromatography). If a compound of formula I comprising pyridyl groups in ring I and in the pendant ring is treated with MCPBA as described above, di-N-oxides will be prepared.
- R 11 is Br, R 5 is hydrogen and R 6 is C-i-C ⁇ alkyl, aryl or heteroaryl;
- R 5 is Ci-C ⁇ alkyl, aryl or heteroaryl and R 6 is hydrogen; R 5 and R 6 are independently selected from the group consisting of C-
- R 9 is H, Ci-C ⁇ alkyl or phenyl; with a compound of the formula
- R 1 a , R 2a , R 3a and R 4a are independently selected from the group consisting of hydrogen and halo and R 7 is Cl or Br, in the presence of a strong base to obtain a compound of the formula
- step (b) reacting a compound of step (a) with (i) POCI3 to obtain a cyano compound of the formula
- L is a leaving group selected from the group consisting of Cl and Br, to obtain an aldehyde or an alcohol of the formula below, respectively:
- R 11 a , R 1 a , R 2a , R 3a and R 4a are independently selected from the group consisting of hydrogen and halo, can be prepared by the following process comprising :
- R 1 a , R 2a , R 3a , R 4a and R 7 are as defined above, in the presence of a strong base to obtain a compound of the formula
- step (c) cyclizing a compound of step (b) with a reagent of the formula R 8 MgL, wherein R 8 is C-f -C ⁇ alkyl, aryl or heteroaryl and L is Br or Cl, provided that prior to cyclization, compounds wherein R 5 or R 6 is hydrogen are reacted with a suitable N-protecting group.
- (+)-lsomers of compounds of formula II wherein X is CH can be prepared with high enantioselectivity by using a process comprising enzyme catalyzed transesterification.
- a racemic compound of formula II, wherein X is C, the double bond is present and V is not H is reacted with an enzyme such as Toyobo LIP-300 and an acylating agent such as trifluoroethly isobutyrate; the resultant (+)-amide is then hydrolyzed, for example by refluxing with an acid such as H2SO4, to obtain the corresponding optically enriched (+)-isomer wherein X is CH and V is not H.
- a racemic compound of formula II wherein X is C, the double bond is present and V is not H, is first reduced to the corresponding racemic compound of formula II wherein X is CH and then treated with the enzyme (Toyobo LIP-300) and acylating agent as described above to obtain the (+)-amide, which is hydrolyzed to obtain the optically enriched (+)-isomer.
- the enzyme Toyobo LIP-300
- acylating agent as described above
- the racemic title compound of Step C is separated by preparative chiral chromatography (Chiralpack AD, 5 cm X 50 cm column, flow rate 100 mL/min. , 20% iPrOH/hexane + 0.2% diethylamine), to give 9.14 g of the (+)-isomer and 9.30 g of the (-)-isomer.
- Step F Combine 8.6 g (21.4 mmol) of the product of Step D and 300 mL of MeOH and cool to 0°-2°C. Add 1.21 g (32.1 mmol) of NaBH 4 and stir at ⁇ 0°C for 1 hr. Add another 0.121 g (3.21 mmol) of NaBH 4 , stir for 2 hr. at 0°C, then let stand overnight at 0°C. Concentrate in vacuo to a residue then partition the residue between CH2CI2 and water. Separate the organic phase and concentrate in vacuo (50°C) to give 8.2 g of the product. Step F:
- Example 1 Step D, and 300 mL of toluene at 20°C, then add 32.5 mL (32.5 mmol) of a 1 M solution of DIBAL in toluene. Heat the mixture at reflux for 1 hr., cool to 20°C, add another 32.5 mL of 1 M DIBAL solution and heat at reflux for 1 hr. Cool the mixture to 20°C and pour it into a mixture of 400 g of ice, 500 mL of EtOAc and 300 mL of 10% NaOH
- Step 1 4-Methyl-3-(Diisopropylcarboxamido)Pyridine
- Step 3 Benzyl 4-Methylnicotinate
- Step 4 Lithium 3-(Benzyloxycarbonyl)-4-Pyridylacetate
- Step 5 Dissolve the product of Step 3 in anhydrous THF (50 mL), cool to -78°C and add dropwise to a solution of lithium diisopropylamide (1.1 mmol) in anhydrous THF (10 mL). After stirring the reaction mixture at -78°C for 1 hour, pour the solution over a slurry of dry ice in anhydrous E.2O and allow the reaction mixture to warm to room temperature over night. Filter the resulting precipitate, wash with E.2O and dry under vacuum to afford the title compound. Step 5:
- Example 2 To the product of Example 2 (1.0 mmol) dissolved in anhydrous DMF add solid K 2 C0 3 (1.2 mmol, anhydrous) and CH3I (1.2 mmol). After stirring the reaction mixture at room temperature for 24 hours, concentrate the mixture in vacuo, dilute with CH2CI2 and wash with water. Dry the organic phase over anhydrous MgS ⁇ 4, filter and concentrate in vacuo to afford the title compound.
- FPT IC50 (inhibition of farnesyl protein transferase, in vitro enzyme assay), COS Cell IC 50 (Cell-Based Assay), GGPT IC 50 (inhibition of geranylgeranyl protein transferase, in vitro enzyme assay), Cell Mat
- inert, pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
- the powders and tablets may be comprised of from about 5 to about 70 percent active ingredient.
- Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.
- Liquid form preparations may also include solutions for intranasal administration.
- Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
- a pharmaceutically acceptable carrier such as an inert compressed gas.
- transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. Preferably the compound is administered orally.
- the pharmaceutical preparation is in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
- the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 300 mg, according to the particular application.
- the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
- a typical recommended dosage regimen is oral administration of from 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to block tumor growth.
- the compounds are non-toxic when administered within this dosage range.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU80584/98A AU8058498A (en) | 1997-06-17 | 1998-06-15 | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors) |
EP98928890A EP0989977A1 (en) | 1997-06-17 | 1998-06-15 | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors) |
CA002293482A CA2293482A1 (en) | 1997-06-17 | 1998-06-15 | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors) |
JP50449899A JP2002504149A (en) | 1997-06-17 | 1998-06-15 | Carboxypiperidyl acetamide tricyclic compounds (farnesyl protein transferase inhibitors) useful for inhibiting G-protein function and treating proliferative diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/877,336 | 1997-06-17 | ||
US08/877,336 US5877177A (en) | 1997-06-17 | 1997-06-17 | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998057946A1 true WO1998057946A1 (en) | 1998-12-23 |
Family
ID=25369775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011503 WO1998057946A1 (en) | 1997-06-17 | 1998-06-15 | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors) |
Country Status (7)
Country | Link |
---|---|
US (1) | US5877177A (en) |
EP (1) | EP0989977A1 (en) |
JP (1) | JP2002504149A (en) |
CN (1) | CN1267289A (en) |
AU (1) | AU8058498A (en) |
CA (1) | CA2293482A1 (en) |
WO (1) | WO1998057946A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451801B1 (en) | 1999-03-26 | 2002-09-17 | Ucb, S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
US6686502B1 (en) | 1999-03-26 | 2004-02-03 | Ucb S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
WO2014006945A1 (en) | 2012-07-04 | 2014-01-09 | アグロカネショウ株式会社 | 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US6323206B1 (en) | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
US6509346B2 (en) | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AU2331999A (en) | 1998-01-21 | 1999-08-09 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
AU2335699A (en) | 1998-01-21 | 1999-08-09 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
US6613905B1 (en) | 1998-01-21 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US7271176B2 (en) * | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
US6271378B1 (en) | 1998-12-18 | 2001-08-07 | Schering Corporation | Process for preparing tricyclic compounds having antihistaminic activity |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US7541365B2 (en) * | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
TWI291467B (en) * | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
US20070148660A1 (en) * | 2005-06-16 | 2007-06-28 | The Regents Of The University Of California | Treatment of maladaptive substance use with H-ras antagonists |
US9365553B2 (en) | 2010-05-27 | 2016-06-14 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and H1 receptor antagonist |
CN103435541B (en) * | 2013-09-09 | 2015-01-14 | 湖北吉和昌化工科技有限公司 | Synthesis method of 1-benzylpyridinium-3-carboxylate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995010516A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030362A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030363A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1997023478A1 (en) * | 1995-12-22 | 1997-07-03 | Schering Corporation | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968690A (en) * | 1986-05-27 | 1990-11-06 | United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services | 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it |
US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
DE69429440T2 (en) * | 1993-10-15 | 2002-08-08 | Schering Corp | TRICYCLIC SULFONAMIDE DERIVATIVES FOR INHIBITING THE G-PROTEIN FUNCTION AND FOR TREATING PROLIFERATIVE DISEASES |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
DK0723538T3 (en) * | 1993-10-15 | 2002-03-18 | Schering Corp | Tricyclic carbamate compounds useful for inhibition of G protein function and for the treatment of proliferative diseases |
US5661152A (en) * | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US5684013A (en) * | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
-
1997
- 1997-06-17 US US08/877,336 patent/US5877177A/en not_active Expired - Fee Related
-
1998
- 1998-06-15 AU AU80584/98A patent/AU8058498A/en not_active Abandoned
- 1998-06-15 WO PCT/US1998/011503 patent/WO1998057946A1/en not_active Application Discontinuation
- 1998-06-15 CN CN98808185A patent/CN1267289A/en active Pending
- 1998-06-15 CA CA002293482A patent/CA2293482A1/en not_active Abandoned
- 1998-06-15 JP JP50449899A patent/JP2002504149A/en active Pending
- 1998-06-15 EP EP98928890A patent/EP0989977A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995010516A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030362A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030363A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1997023478A1 (en) * | 1995-12-22 | 1997-07-03 | Schering Corporation | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
Non-Patent Citations (3)
Title |
---|
BISHOP W R ET AL: "NOVEL TRICYCLIC INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BIOCHEMICAL CHARACTERIZATION AND INHIBITION OF RAS MODIFICATION IN TRANSFECTED COS CELLS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 51, 22 December 1995 (1995-12-22), pages 30611 - 30618, XP002050604 * |
NJOROGE F G ET AL: "DISCOVERY OF NOVEL NONPEPTIDE TRICYCLIC INHIBITORS OF RAS FARNESYL PROTEIN TRANSFERASE", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 5, no. 1, 1997, pages 101 - 113, XP002056551 * |
NJOROGE F G ET AL: "NOVEL TRICYCLIC AMINOACETYL AND SULFONAMIDE INHIBITORS OF RAS FARNESYL PROTEIN TRANSFERASE", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 24, 1996, pages 2977 - 2982, XP002056550 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451801B1 (en) | 1999-03-26 | 2002-09-17 | Ucb, S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
US6686502B1 (en) | 1999-03-26 | 2004-02-03 | Ucb S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
US6797713B2 (en) | 1999-03-26 | 2004-09-28 | Ucb S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
WO2014006945A1 (en) | 2012-07-04 | 2014-01-09 | アグロカネショウ株式会社 | 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient |
KR20150042781A (en) | 2012-07-04 | 2015-04-21 | 아구로카네쇼 가부시키가이샤 | 2-Aminonicotinic acid ester derivative and bactericide containing same as active ingredient |
US9096528B2 (en) | 2012-07-04 | 2015-08-04 | Agro-Kanesho Co., Ltd. | 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
JP2002504149A (en) | 2002-02-05 |
CN1267289A (en) | 2000-09-20 |
CA2293482A1 (en) | 1998-12-23 |
US5877177A (en) | 1999-03-02 |
AU8058498A (en) | 1999-01-04 |
EP0989977A1 (en) | 2000-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6239140B1 (en) | Compounds useful for inhibition of farnesyl protein transferase | |
US5945429A (en) | Compounds useful for inhibition of farnesyl protein transferase | |
US6051582A (en) | Compounds useful for inhibition of farnesyl protein transferase | |
US5877177A (en) | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
EP0927178B1 (en) | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
EP1019400B1 (en) | Benzo(5,6)cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors | |
US5925639A (en) | Keto amide derivatives useful as farnesyl protein transferase inhibitors | |
EP0934303B1 (en) | Compounds useful for inhibition of farnesyl protein transferase | |
EP0931079B1 (en) | Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase | |
WO1998011106A1 (en) | Tricyclic compounds useful as fpt inhibitors | |
EP0991644B1 (en) | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors | |
US5958890A (en) | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
CA2293372C (en) | Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase | |
EP0927179B1 (en) | Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase | |
EP0993454B1 (en) | Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase | |
US20030092726A1 (en) | Compounds useful for inhibition of farnesyl protein transferase | |
WO1998057964A1 (en) | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
MXPA99012089A (en) | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors) | |
MXPA99012087A (en) | Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98808185.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2293482 Country of ref document: CA Ref document number: 2293482 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/012089 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998928890 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998928890 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998928890 Country of ref document: EP |